Investors

Newmont Corporation Investors Urged to Join Securities Fraud Lawsuit Following Stock Plunge; Levi & Korsinsky Lead Charge Before April Deadline

by

New York, NY – A class action lawsuit has been initiated by Levi & Korsinsky, LLP against Newmont Corporation, a prominent player in the mining sector, alleging securities fraud damaging to investors. The legal challenge, aimed at addressing financial losses faced by Newmont’s stakeholders, covers a period from February 22, 2024, to October 23, 2024. The complexities of the lawsuit surface following a significant announcement by Newmont on October 23, 2024, where the company reported disappointing financial results for the third quarter of the year. Alongside lower-than-expected earnings before interest, taxes, depreciation, and amortization (EBITDA), … Read more

Investors Called to Lead Class Action Suit Against Alarum Technologies for Alleged Securities Fraud

by

Los Angeles, CA – ALAR Investors are presented with a significant opportunity to assume a lead role in a securities fraud class action lawsuit against Alarum Technologies Ltd. The legal action, facilitated by The Schall Law Firm, alleges that the technology company engaged in fraudulent activities that misled investors about its financial and operational status. The lawsuit is open to investors who purchased securities in Alarum Technologies between February 10, 2021, and February 10, 2023. The claim centers around accusations that Alarum presented falsely inflated business prospects and operational successes which in turn affected the … Read more

PCRX Investors Invited to Head Class Action Lawsuit Against Pacira BioSciences Over Alleged Securities Fraud

by

Investors in Pacira BioSciences, Inc., a New Jersey-based pharmaceutical company, have been granted the opportunity to lead a securities class action lawsuit over allegations of fraudulent activity. The lawsuit surrounds claims that Pacira misrepresented its financial status and the efficacy of certain products, thereby inflating its stocks artificially. The legal challenge roots from assertions that Pacira failed to disclose operational and business setbacks, particularly concerning the effectiveness and market acceptance of EXPAREL, a non-opioid pain management drug that is one of the company’s top products. Allegedly, the company made misleading statements or failed to provide … Read more

Investors Alert: Join Pacira BioSciences Class Action Lawsuit by March 14, 2025 – Legal Representation Available Through The Gross Law Firm for PCRX Shareholders

by

Investors in Pacira BioSciences, Inc. are facing critical financial concerns following allegations of securities fraud, prompting a class action lawsuit that demands immediate attention. With a deadline of March 14, 2025, for Pacira’s shareholders to contact The Gross Law Firm to discuss their legal options, time is of the essence for those impacted by the company’s recent stock performance issues. Pacira BioSciences, known for its non-opioid pain management drugs, has come under legal scrutiny after accusations surfaced that the company may have misled investors about its business and financial prospects. These allegations suggest that Pacira … Read more